» Articles » PMID: 28597167

Predictors of Thrombohemorrhagic Early Death in Children and Adolescents with T(15;17)-positive Acute Promyelocytic Leukemia Treated with ATRA and Chemotherapy

Abstract

Clinical trials on childhood acute promyelocytic leukemia (APL) report early death (ED) rates of 3-8%, but predictors of thrombohemorrhagic (TH)-ED are not well understood. In a retrospective study, we aimed to determine the incidence and predictors of TH-ED in childhood APL. Data were analyzed from children and adolescents with t(15;17)-positive APL (n = 683) who started treatment with all-trans retinoic acid (ATRA) and chemotherapy in different international studies. Demographic data; initial white blood cell (WBC), peripheral blood (PB) blast, and platelet counts; hemoglobin value; coagulation parameters; morphologic variant (M3 or M3v); and induction details were analyzed. Early death was defined as death occurring within 30 days of presentation. The incidence of ED was 4.7% (32 of 683 patients). Predictors of TH-ED were identified by univariable and multivariable Cox proportional hazard regression analyses (n = 25). In univariable analysis, high WBC (>10 × 10/L) (P < 0.001) and high PB blast (>30 × 10/L) (P < 0.001), M3v (P < 0.01), and black ethnicity (P < 0.001) were independent predictors of TH-ED. In multivariable analysis, high WBC count (P < 0.01) and obesity (i.e., body mass index ≥95th percentile for age) (P = 0.03) were predictors of TH-ED. Initial high WBC counts and obesity are likely predictors of TH-ED in childhood APL. The efficacy of novel drugs for APL-associated coagulopathy or of frontline arsenic trioxide and ATRA combination regimens in reducing ED rates in childhood APL remains to be established.

Citing Articles

Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all- retinoic acid.

Silva W, Kim H, Undurraga M, Navarro-Cabrera J, Salinas V, Muxi P Haematologica. 2024; 110(3):795-798.

PMID: 39479861 PMC: 11873706. DOI: 10.3324/haematol.2024.286338.


The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management.

Hermsen J, Hambley B Cancers (Basel). 2023; 15(13).

PMID: 37444587 PMC: 10340352. DOI: 10.3390/cancers15133477.


Nutritional Status at Diagnosis as Predictor of Survival from Childhood Cancer: A Review of the Literature.

Karalexi M, Markozannes G, Tagkas C, Katsimpris A, Tseretopoulou X, Tsilidis K Diagnostics (Basel). 2022; 12(10).

PMID: 36292046 PMC: 9600212. DOI: 10.3390/diagnostics12102357.


Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial.

Luo S, Tian J, Sun X, Wu F, Liu Y, Wan W Evid Based Complement Alternat Med. 2022; 2022:8314176.

PMID: 35836830 PMC: 9276483. DOI: 10.1155/2022/8314176.


An Outcome Analysis of Childhood Acute Promyelocytic Leukemia Treated with Atra and Arsenic Trioxide, and Limited Dose Anthracycline.

Jabbar N, Khayyam N, Arshad U, Maqsood S, Hamid S, Mansoor N Indian J Hematol Blood Transfus. 2021; 37(4):569-575.

PMID: 34744341 PMC: 8523738. DOI: 10.1007/s12288-021-01404-1.